Skip to main navigation Skip to search Skip to main content

A Multinational, Multicenter, Prospective, Randomized Controlled, Open Label Phase 3 Study with Best Standard of Care with and without 177Lu-DOTA-Rosopatamab for Patients with PSMA Expressing Metastatic Castration-Resistant Prostate Cancer Progressing Despite Prior Treatment with A Novel Androgen AXIS Drug

  • Liow, Elizabeth (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusActive
Effective start/end date1/12/23 → 30/11/28

Clinical Trial Phase

  • Phase III (a & b)